Panellists in this video:
• Mr Suresh Pattathil, MD & GM, AbbVie India (MODERATOR)
• Dr Villoo Morawala Patell, Founder, Avesthagen and Avestagenome Project International
• Dr Rhonda Duffy, COO, Biocon
• Dr Murali Ramachandra, CEO, Aurigene Oncology
Key Highlights:
[1] India’s pharma industry needs to move from volume and cost leadership towards innovation, originality and value creation.
[2] India’s genetic diversity and population data present a unique opportunity to discover novel drug targets, molecules and precision therapies.
[3] Cancer, diabetes, rare diseases and antimicrobial resistance are key areas where India can build leadership in innovative therapeutics.
[4] Greater risk capital, long-term funding and stronger industry–academia–government collaboration are essential to take innovations from discovery to market.
[5] Faster regulatory processes, ease of doing business and stronger IP/data protection will be critical for India to build a globally competitive innovation ecosystem.